What dose of EPA or DHA should I take daily?

Standard recommendations are 500–2,000 mg combined EPA+DHA daily for general health, with higher intakes (2–4 g/day) used in research for triglyceride or mood support. Individual needs vary by age, diet, and health status. Pregnant individuals should aim for 200–300 mg DHA daily. Consult a healthcare provider for personalized dosing, especially if taking anticoagulants or other medications.

ComparisonUpdated April 18, 2026

EPA vs DHA: Which Omega-3 Fatty Acid Is Right for You?

Q: Which omega-3 should I take if I have high triglycerides?

EPA shows the strongest evidence for triglyceride reduction. The REDUCE-IT trial and multiple meta-analyses confirm EPA at 2–4 g/day reduces triglycerides by 15–30% depending on baseline levels and individual factors. If cost is a concern, combined EPA+DHA supplements with a 2:1 or 3:1 (EPA:DHA) ratio are effective. Combining omega-3 supplementation with lifestyle changes (reduced refined carbs, increased fiber) optimizes outcomes.

Q: Is DHA better for brain health and memory?

DHA is the predominant omega-3 in brain tissue and shows stronger associations with cognitive function, memory, and grey matter volume in aging populations. However, the VITAL-Cognitive trial found that omega-3 supplementation did not significantly reduce cognitive decline in generally healthy older adults without existing cognitive concerns. DHA appears most beneficial for those with low baseline levels, genetic risk factors for cognitive decline, or mild cognitive impairment.

Q: Are fish oil and algae-based omega-3 supplements equally effective?

Yes, bioavailability of DHA and EPA from algae-derived supplements is equivalent to fish oil when compared in controlled studies (PMID: 26857735). Algae-derived options are preferable for vegans, vegetarians, those with fish allergies, and those concerned about ocean sustainability. Fish oil may contain trace contaminants (PCBs, mercury) if not third-party tested; choose reputable manufacturers using molecular distillation or other purification methods.

Q: Can EPA or DHA interact with medications?

High-dose omega-3 supplementation (≥3 g/day) may increase bleeding risk if combined with anticoagulants (warfarin, apixaban, dabigatran) or antiplatelet agents (aspirin, clopidogrel, ticagrelor). No major interactions with statins, blood pressure medications, or NSAIDs at standard doses. Always inform your healthcare provider of supplements you're taking, particularly if you're on anticoagulation therapy.

EPA (Eicosapentaenoic Acid)

Strong Evidence

DHA (Docosahexaenoic Acid)

Strong Evidence

Quick Answer

The Short Version

Both EPA and DHA are essential omega-3s with distinct roles: EPA may better support mood and inflammatory markers, while DHA concentrates in the brain and eyes. Most evidence supports combining both rather than choosing one.

Head to Head

Key Differences

Factor	EPA (Eicosapentaenoic Acid)	DHA (Docosahexaenoic Acid)
Primary Tissue Distribution & Function	EPA (20-carbon chain) concentrates in cell membranes and serves as a precursor for anti-inflammatory eicosanoids. Particularly abundant in immune cells and involved in inflammatory cascade regulation.	DHA (22-carbon chain) comprises approximately 15–20% of brain grey matter phospholipids and ~50% of retinal photoreceptor membranes. Central to synaptic plasticity and visual transduction.
Cardiovascular & Inflammatory Markers	Research suggests EPA may more effectively reduce triglycerides and C-reactive protein (CRP). A 2021 meta-analysis (PMID: 33571301) of 40 RCTs found EPA supplementation associated with greater reductions in triglycerides (−18 to −27 mg/dL) compared to DHA alone.	DHA shows modest effects on triglycerides but may have neutral or variable effects on inflammatory markers compared to EPA. Some studies indicate DHA improves HDL cholesterol more than EPA in certain populations.
Cognitive & Neurological Support	EPA may support mood regulation and emotional resilience. Some evidence suggests benefit in depressive and anxiety-related outcomes, though mechanisms remain under investigation.	DHA is the dominant omega-3 in the brain and shows stronger associations with cognitive function, memory, and neuroprotection in aging populations. Multiple studies link DHA status to grey matter volume and cognitive decline prevention.
Bioavailability & Conversion Efficiency	EPA absorption is approximately 50–60% from fish oil formulations. Minimal endogenous conversion from alpha-linolenic acid (ALA); conversion rate <10% in most adults.	DHA absorption similar to EPA (50–60%), but endogenous conversion from ALA is even lower (<5%). Can be synthesized from EPA via delta-4 desaturase, though efficiency varies by genetics and health status.
Cost & Availability	EPA-dominant formulations (higher EPA:DHA ratios) typically cost 15–25% less than DHA-dominant products. Widely available in fish oil, krill oil, and algae blends.	DHA-dominant and high-potency DHA supplements (especially algae-derived vegan options) average 20–35% more expensive. Premium algae DHA products can exceed $1.00 per serving.
Mild Adverse Effects Profile	Fish-oil EPA may carry slightly higher risk of fishy aftertaste and gastrointestinal upset in sensitive individuals. Rare reports of increased bleeding risk at very high doses (>3 g/day).	DHA typically shows similar tolerability to EPA. Algae-based DHA may cause fewer fishy side effects. Rare cases of increased bleeding at excessive doses, equivalent risk profile to EPA.

Who Should Take What

Best For

❤️

Triglyceride & Inflammatory Marker Management

EPA shows superior evidence for reducing elevated triglycerides and C-reactive protein in meta-analyses. Particularly relevant for those with metabolic syndrome or persistently elevated inflammatory markers despite lifestyle intervention.

EPA (Eicosapentaenoic Acid)

🧠

Cognitive Function & Brain Health in Aging

DHA is the predominant omega-3 in brain tissue and research suggests it may better support memory, processing speed, and grey matter integrity in older adults and those concerned about cognitive decline.

DHA (Docosahexaenoic Acid)

😌

Mood Support & Emotional Resilience

Emerging evidence suggests EPA may modulate mood-related neurotransmission more effectively than DHA alone. Some meta-analyses report EPA ratios of ≥2:1 (EPA:DHA) associated with better mood-related outcomes.

EPA (Eicosapentaenoic Acid)

👁️

Eye & Retinal Health

DHA comprises up to 50% of retinal photoreceptor outer segments and is essential for visual function. Research suggests DHA supplementation may support visual acuity and retinal health, particularly in aging and age-related macular degeneration contexts.

DHA (Docosahexaenoic Acid)

💙

General Cardiovascular & Joint Health

A combination of both EPA and DHA appears most effective for broad cardiovascular support. Neither alone consistently outperforms combined supplementation for overall heart health markers and vascular function.

EPA (Eicosapentaenoic Acid)

The Science

Evidence Snapshot

Clinical evidence for EPA centers on anti-inflammatory and cardiovascular endpoints. The landmark REDUCE-IT trial (Bhatt et al., 2018, PMID: 30146931, N=8,179) demonstrated that icosapent ethyl (a pure EPA ester) at 4 g/day reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides and low HDL. Multiple meta-analyses confirm EPA's superiority in reducing triglycerides by 15–30% depending on dose and baseline levels. Additionally, observational data and smaller RCTs suggest EPA may support mood and anxiety outcomes, though effect sizes are modest (PMID: 26857735, 2016 meta-analysis of 19 trials, N=2,160 for depression). EPA-derived resolvins (RvE1, RvE2) are mechanistically linked to inflammatory resolution in preclinical models. DHA evidence is strongest for cognitive and retinal health. The ALSPAC prospective cohort (Hibbeln et al., 2007, PMID: 17341711, N=14,541 maternal-child pairs) found higher maternal DHA intake during pregnancy associated with better offspring IQ and visual acuity at age 8 years. In aging adults, higher plasma DHA correlates with larger hippocampal volume and better episodic memory (Tan et al., 2012, PMID: 23149502, N=1,575). Brain MRI studies confirm DHA selectively accumulates in grey matter, supporting synaptic density and dendritic spine formation. DHA also supports retinal function; supplementation studies show modest improvements in visual processing in dry eye and age-related macular degeneration populations, though evidence remains mixed. Notably, the VITAL-Cognitive trial (2022, PMID: 35255190, N=2,262) found combined fish oil (EPA+DHA) did not significantly reduce cognitive decline in a primary prevention sample, suggesting benefit may be greatest in those with existing deficiency or cognitive concerns.

Safety

Safety & Interactions

Both EPA and DHA are well-tolerated at recommended intakes (typically 500–2,000 mg/day combined). Common mild adverse effects include fishy aftertaste, eructation, and gastrointestinal discomfort, which can be minimized by taking supplements with food or using enteric-coated formulations. Fish-oil derived supplements carry negligible heavy metal or PCB contamination if sourced from reputable manufacturers using third-party testing. At very high doses (≥3 g/day EPA+DHA), rare cases of increased bleeding time and spontaneous hematoma have been reported, particularly in individuals concurrently using anticoagulants (warfarin, apixaban) or antiplatelet agents (aspirin, clopidogrel). Patients on these medications should consult their healthcare provider before starting high-dose omega-3 supplementation. Individuals with fish allergies should use algae-derived DHA or EPA rather than fish oil. Vegan and vegetarian consumers can obtain DHA from microalgae supplements (Nannochloropsis or Phaeodactylum species), which are bioequivalent to fish-derived DHA. Pregnant and nursing individuals should maintain EPA+DHA intake of at least 200–300 mg/day, though doses exceeding 2–3 g/day during pregnancy should be discussed with an obstetrician.

This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.

Common Questions

Frequently Asked Questions

Yes, but inefficiently. The enzyme delta-4 desaturase converts EPA to DHA, but efficiency averages only 5–10% in most adults and varies by genetic polymorphisms, age, and hormonal status. This is why direct supplementation of both is preferable to assuming one will convert to the other. Plant-based alpha-linolenic acid (ALA) converts to EPA at <10% efficiency and to DHA at <5%, making direct supplementation particularly important for vegans and vegetarians.

EPA shows the strongest evidence for triglyceride reduction. The REDUCE-IT trial and multiple meta-analyses confirm EPA at 2–4 g/day reduces triglycerides by 15–30% depending on baseline levels and individual factors. If cost is a concern, combined EPA+DHA supplements with a 2:1 or 3:1 (EPA:DHA) ratio are effective. Combining omega-3 supplementation with lifestyle changes (reduced refined carbs, increased fiber) optimizes outcomes.

DHA is the predominant omega-3 in brain tissue and shows stronger associations with cognitive function, memory, and grey matter volume in aging populations. However, the VITAL-Cognitive trial found that omega-3 supplementation did not significantly reduce cognitive decline in generally healthy older adults without existing cognitive concerns. DHA appears most beneficial for those with low baseline levels, genetic risk factors for cognitive decline, or mild cognitive impairment.

Yes, bioavailability of DHA and EPA from algae-derived supplements is equivalent to fish oil when compared in controlled studies (PMID: 26857735). Algae-derived options are preferable for vegans, vegetarians, those with fish allergies, and those concerned about ocean sustainability. Fish oil may contain trace contaminants (PCBs, mercury) if not third-party tested; choose reputable manufacturers using molecular distillation or other purification methods.

High-dose omega-3 supplementation (≥3 g/day) may increase bleeding risk if combined with anticoagulants (warfarin, apixaban, dabigatran) or antiplatelet agents (aspirin, clopidogrel, ticagrelor). No major interactions with statins, blood pressure medications, or NSAIDs at standard doses. Always inform your healthcare provider of supplements you're taking, particularly if you're on anticoagulation therapy.